# BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

> **NCT03771885** · PHASE1 · WITHDRAWN · sponsor: **Boehringer Ingelheim**

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** BI 705564
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03771885
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-03-16
- **Primary completion:** 2019-12-21
- **Final completion:** 2020-01-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Based on a strategic decision, the application for the trial has been withdrawn before initiation.
- **Last updated:** 2021-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03771885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03771885, "BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03771885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*